Anatomic Pathology Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The anatomic pathology market size is projected to reach US$ 53.27 billion by 2031 from US$ 30.22 billion in 2023. The market is expected to register a CAGR of 7.3% during 2023–2031. The integration of artificial intelligence and machine learning is likely to act as a future trend in the market.

Anatomic Pathology Market Analysis

Innovations in diagnostic techniques—including digital pathology, molecular diagnostics, and imaging technologies—enhance the accuracy and efficiency of pathology services, propelling the anatomic pathology market growth. An aging population is more susceptible to various diseases, leading to increased demand for pathology services for accurate diagnosis and treatment planning. In addition, increased awareness about health issues, robust screening programs contributing to early diagnosis, supportive regulatory frameworks, and favorable reimbursement policies are fueling the growth of the anatomic pathology market.

Anatomic Pathology Market Overview

India is expected to register the highest CAGR in the overall market. The National Cancer Registry Programme Report 2020 projected cancer cases in India to reach 14.61 million in 2022. The report also stated that the incidence of cancer is estimated to increase by 12.8% by 2025 compared to 2020. With the surging prevalence of cancer and advancements in healthcare infrastructure, government authorities in India are focusing on providing people with extended access to healthcare solutions. As per data by the Department for Promotion of Industry and Internal Trade (DPIIT), the inflow of foreign direct investments (FDIs) into the drugs and pharmaceuticals industry totaled US$ 17.74 billion from April 2000 to December 2020. Moreover, companies, organizations, governments, etc., make significant investments in diagnostic services and modern diagnostic facilities. Thus, such investments in the healthcare sector bolster the anatomic pathology market growth in India.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Anatomic Pathology Market: Strategic Insights

Anatomic Pathology Market

• 
  CAGR (2023 - 2031)

  7.3%
• Market Size 2023
  US$ 30.22 Billion
• Market Size 2031
  US$ 53.27 Billion

Market Dynamics

GROWTH DRIVERS

• Increase in Prevalence of Cancer and Kidney Diseases

FUTURE TRENDS

• The integration of artificial intelligence and machine learning

OPPORTUNITIES

• Growing Focus on Personalized Medicines

Key Players

• F Hoffmann La Roche Ltd
• Beckman Coulter Inc
• Hologic Inc
• Agilent Technologies Inc
• BioGenex Laboratories Inc
• Diapath S p A
• Bio SB
• Merck KGaA
• BD
• PHC Holdings Corporation

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Product and Services

• Services
• Instruments
• Consumables

Application

• Disease Diagnosis
• Drug Discovery and Development

End User

• Hospitals
• Research Laboratories
• Diagnostic Laboratories

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Anatomic Pathology Market Drivers and Opportunities

Increase in Prevalence of Cancer and Kidney Diseases

Anatomic pathology is useful in identifying abnormalities that can help diagnose diseases, such as autoimmune diseases, kidney and liver diseases, and cancer. Histopathology, which involves studying tissue changes caused by diseases, is a vital part of anatomic pathology. Cancer has a major impact on society across the world. The burden of cancer on healthcare systems is significantly increasing worldwide as it is among the leading causes of death. The World Health Organization (WHO) ranks cancer as the second-leading cause of mortality worldwide. According to data published by the World Cancer Research Fund International, ~20 million new cases of cancer were registered in 2022 globally. Moreover, as per the data published by the World Health Organization (WHO), nearly 10 million deaths worldwide were caused by cancer in 2020. The National Center for Health Statistics data estimates that the diagnosis of new cancer cases in the US is likely to reach 2 million in 2024. In addition, ~0.61 million people are likely to die in 2024 in the US due to cancer. According to data published by Macmillan Cancer Support, ~392,000 people in the UK are diagnosed with cancer every year, while ~167,000 people die due to the disease each year.

The prevalence of chronic kidney disease is growing due to the increase in the geriatric population. According to the Centers for Disease Control and Prevention, in 2023, ~35.5 million people in the US suffered from chronic kidney diseases. Biopsy, an anatomic pathology technique, is used for the detection of cancer and chronic kidney disease. Owing to the increasing prevalence of cancer and kidney disease, government agencies, healthcare providers, and institutions are being compelled to contribute toward disease diagnosis and treatment initiatives. Thus, a surge in the prevalence of cancer and other targeted diseases, such as autoimmune diseases, and kidney and liver diseases is driving the global anatomic pathology market growth.

Growing Focus on Personalized Medicines to Offer Opportunity for Market

Personalized medicines are mainly designed by considering individuals' genetic profiles to guide the decisions made with respect to the prevention, diagnosis, and treatment of a disease. They provide an opportunity for drug manufacturers to develop agents that target patient groups that do not respond to medications as intended or for them who do not respond as expected to traditional healthcare practices. There is much evidence indicating that a substantial portion of the variability in drug response depends on factors that are genetically controlled, including age, nutrition, environmental exposure, and health status. Genomics plays an important role in the emergence of personalized medicines, as having the knowledge of a patient's genetic profile would help doctors in selecting an apt medication. Personalized medicines are helpful in improving healthcare by enabling each patient to receive earlier diagnoses, risk assessments, and optimal treatments.

Pathologists play an important role in developing and implementing molecular and genomic tests in practice. Personalized medicines are used in the treatment of diseases such as breast cancer and cardiovascular diseases. Personalized anticancer medicines exhibit fewer and less severe side effects than other types of treatment as they are designed for more specific action. Further, with the ongoing progress in research and clinical studies, personalized medicines are likely to reach even greater potential to improve the quality of patient care. Thus, the growing focus on personalized medicines is expected to boost the anatomic pathology market growth.

Anatomic Pathology Market Report Segmentation Analysis

Key segments that contributed to the derivation of the anatomic pathology market analysis are products and services, application, and end user.

• Based on products and services, the anatomic pathology market is segmented into instruments, consumables, and services. The services segment is further bifurcated into histopathology and cytopathology. The instruments segment is further divided into microtomes and cryostat, automatic stainers, tissue processors, and others. The instruments segment held the largest market share in 2023.
• By application, the market is segmented into disease diagnosis, drug discovery and development, and others. The disease diagnosis segment held the largest market share in 2023.
• Based on end user, the anatomic pathology market is divided into hospitals, research laboratories, diagnostic laboratories, and others. The hospitals segment held the largest market share in 2023.

Anatomic Pathology Market Share Analysis by Geography

The geographic scope of the anatomic pathology market report is mainly divided into five regions: North America, Asia Pacific, Europe, the South & Central America, and the Middle East & Africa. North America dominated the market in 2023. The growth of the market in this region is attributed to the growing prevalence of cancer, increasing government initiatives for screening cancer patients, rising focus on efficient disease diagnosis, and surging need for advanced healthcare systems. Moreover, increased research and development efforts undertaken by the market players, coupled with product launches, are likely to drive the growth of the anatomic pathology market in North America during the forecast period. Players operating in the US anatomic pathology market continuously focus on the development of innovative and convenient instruments and consumables for pathological procedures. In November 2023, Illumina Inc., US, a global leader in DNA sequencing and array-based technologies, introduced TruSight Oncology 500 ctDNA v2 (plate number 1 ctDNA v2), a new version of its distributed liquid biopsy assay that allows comprehensive noninvasive genomic profiling of circulating tumor DNA from blood, complementing tissue-based testing. Asia Pacific is anticipated to register the highest CAGR during the forecast period.

Anatomic Pathology Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Anatomic Pathology Market News and Recent Developments

The anatomic pathology market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the market are listed below:

• Agilent Technologies Inc. partnered with Hamamatsu Photonics K.K., a leading provider of whole slide imaging systems. The collaboration involved incorporating Hamamatsu's NanoZoomer range, including the S360MD Slide scanner system, into Agilent's digital pathology solution. The addition of the NanoZoomer Slide scanner systems, which convert glass slides into high-resolution digital data through high-speed scanning, has completed Agilent's offering of an open and agnostic digital pathology workflow aimed at accelerating breakthroughs in precision medicine. (Source: Agilent Technologies Inc., Company Website, March 2023)
• Epredia, a subsidiary of PHC Corporation, and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announced signing a letter of intent for a U.S. exclusive commercial distribution agreement for MarginScan, a medical device that will support physicians in real-time detection of non-melanoma skin cancer. Epredia has engaged Avantik, a company specializing in supporting diagnostic labs with their operations, to get this new device into the hands of Mohs surgeons. (Source: PHC Corporation, Company Website, May 2024)

Anatomic Pathology Market Report Coverage and Deliverables

The "Anatomic Pathology Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Anatomic pathology market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Anatomic pathology market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PESTand SWOT analysis
• Anatomic pathology market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the anatomic pathology market
• Detailed company profiles